GO
Loading...

Rigel Pharmaceuticals Inc

  • Oct 24- Rigel Pharmaceuticals Inc said it would stop the development of its drug to treat skin lesions in patients with discoid lupus, a chronic skin disease, after the treatment failed a mid-stage trial. British drugmaker AstraZeneca stopped developing Rigel's rheumatoid arthritis treatment, fostamatinib, in June, which it licensed from Rigel in 2010..

  • Rigel to drop skin disease drug after trial failure Thursday, 24 Oct 2013 | 7:55 AM ET

    Oct 24- Rigel Pharmaceuticals Inc said it would stop the development of its drug to treat skin lesions in patients with discoid lupus, a chronic skin disease, after the treatment failed a mid-stage study.

  • Early Movers: AAPL, UNH, MSFT, TM & More Wednesday, 5 Jun 2013 | 7:40 AM ET

    Some of the names on the move ahead of the open.

  • Early Movers: AIG, DELL, DG, FDX, BWLD & More Tuesday, 4 Jun 2013 | 7:32 AM ET

    Some of the names on the move ahead of the open.

  • 5 Stocks Poised for Breakouts: Technical Analysis Monday, 15 Apr 2013 | 4:00 PM ET
    The 3D Systems modeling printer.

    The pros know that once a stock starts to break past resistance levels, it can easily trend significantly higher. TheStreet.com looks at five stocks.

  • MARKET PULSE-Sarepta, HP, Leap, Ocwen, Netflix, Adtran Wednesday, 3 Oct 2012 | 1:54 PM ET

    U.S. stocks advanced on Wednesday after stronger-than-expected employment and service-sector data in the United States. But a gloomier outlook in China and Europe weighed on commodity prices and hit energy and materials shares. **SAREPTA THERAPEUTICS INC, $41.60, up 177 pct.

  • U.S. stocks rose on Wednesday after stronger-than-expected employment and service-sector data in the United States, but a gloomier outlook in China and Europe weighed on commodity prices and hit energy and materials shares. **SAREPTA THERAPEUTICS INC, $40.65, up 171 pct. **HEWLETT-PACKARD CO, $15.67, down 8.4 pct.

  • **SAREPTA THERAPEUTICS INC, $40.19, up 168 pct. **BIOLASE INC, $2.11, up 27 pct. The company said health regulators in Europe and the United States approved its laser device for use in soft tissue surgery, teeth whitening, and pain therapy.

  • Shares of Rigel Pharma fall on stock offering Wednesday, 3 Oct 2012 | 11:15 AM ET

    SOUTH SAN FRANCISCO, Calif.-- Drug developer Rigel Pharmaceuticals Inc. said it priced its public offering of 13.7 million shares of its common stock at $9.50 per share. The South San Francisco, Calif.- based company said it expects the offering's gross proceeds to total about $130 million, before deducting underwriting discounts, commissions, and other expenses.

  • The Nasdaq Composite Index rose 0.37 percent. **SAREPTA THERAPEUTICS INC, $30.30, up 102 pct. **INTERMUNE INC, $9.74, up 10 pct.

  • **SAREPTA THERAPEUTICS INC, Tuesday close $14.99, up 135 pct premarket. **HEWLETT-PACKARD CO, Tuesday close $17.13, up 0.4 pct premarket. **GOOGLE INC, Tuesday close $756.99, up 0.13 pct premarket.

  • Oct 3- Rigel Pharmaceuticals Inc:. *Announces pricing of public offering of common stock. *Says public offering of 13.7 million common shares priced at $9.50 per share.

  • **SAREPTA THERAPEUTICS INC, Tuesday close $14.99, up 135 pct premarket. **HEWLETT-PACKARD CO, Tuesday close $17.13, up 0.4 pct premarket. **GOOGLE INC, Tuesday close $756.99, up 0.13 pct premarket.

  • Oct 2- Rigel Pharmaceuticals Inc:. *Announces proposed public offering of common stock. *Proceeds to be used to fund research and development activities and for.

  • Cramer's Calls on 5 Stocks Thursday, 1 Dec 2011 | 8:03 PM ET

    The "Mad Money" host opens his mailbag and answers viewer's questions.

  • Rivals Gain on Pfizer Drug Trial News Thursday, 21 Apr 2011 | 5:42 PM ET

    I noted on the air this afternoon that Pfizer, which was trading at about $20.20, dropped in a few minutes to about $19.50 on heavy volume.

  • Options Action Points to Hershey, Rigel Pharma Thursday, 7 Aug 2008 | 10:49 AM ET

    Options trading points toward developments at Hershey -- similar to what swirled around Anheuser-Busch -- according to Interactive Brokers' Rebecca Darst.

  • US Stocks Hit by Inflation Worries Friday, 14 Dec 2007 | 4:40 PM ET

    Inflation took the spotlight as the newest fear to haunt investors, sending stocks down to end a volatile week that featured more credit worries and pervasive unease over the Fed's role in the market.

  • Stocks Close Mixed As Dow Rebounds Thursday, 13 Dec 2007 | 3:59 PM ET

    Stocks closed mixed as worries about a weakening economy and credit crunch continued to rattle the markets.

  • It's Time for the Lightning Round! Tuesday, 17 Apr 2007 | 6:38 PM ET

    Cramer's got the call on Bank of America, Jones Soda, AIG and more.Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.

Most Popular Video

Tuesday, 15 Apr 2014 | 6:00 PM ET

Fear and loathing. Mad Money host Jim Cramer looks at fears professional money managers face in the current market environment.

Tuesday, 15 Apr 2014 | 4:00 PM ET

CNBC's Patti Domm sits down with Lindsey Group Chief Market Analyst Peter Boockvar to discuss whether or not inflation could affect the Fed's plans.

Tuesday, 15 Apr 2014 | 3:00 PM ET

CNBC.com Senior Writer John Jannarone talks about what Coca-Cola really needs to do to sustain revenue growth.